T20/C4 Sativa

Dominate Cannabinoids:

Batch FT080322

THC 18%

The G150 hybrid variety was selected from hundreds of varieties that underwent a unique genetic scan. It boasts a dense and shiny inflorescence and produces a fresh pine and lemon aroma.

Dominant Terpenes

B-Caryophyllene is found in a large number of plants such as cloves, rosemary, black pepper and lavender. Scientific literature indicates that b-Caryophyllene aids in the protection of various cells in the nervous system, increasing appetite and ability to manage pain during withdrawal from addictions, such as alcoholism. It also has the potential to treat inflammation, multiple sclerosis and Parkinson’s.


B-Myrcene is found in lemon grass, bay leaves, ylangylang, wild thyme, parsley, cardamom and basil, among others. Research in the field indicates its ability to protect the brain, heart and skin tissues from inflammation and oxidative damage. In addition, it supports pain relief.


Linalool is found in lavender, rose and basil. There is evidence that it has anti-cancer and antioxidant properties and contributes to the reduction of seizures and pain. It can help fight the effects of inflammation and oxidation, protect nerve and liver cells, and expel infections. Linalool is found to have a calming and antidepressant effect.


a-Humulene is a common chemical compound in sage, ginseng, and certain plants in the Hadassi family. It has a particular characteristic aroma – In fact, it’s what gives beer its “hoppy” flavor! Scientific research suggests that terpene and its derivatives show anti-allergic, anti-inflammatory, and anti-cancer potential.

Taste and Aroma


* This information herein does not constitute a binding opinion and should not be relied upon except as a general review, which is not a substitute for a professional medical opinion. CANONIC cannot guarantee and is not responsible that the effects described, or similar effects, will be felt by patients. The information should not be construed as advertisement and / or recommendation and / or encouragement for the use of cannabis, which is a prohibited use by law, other than for medical purposes. The use of medical cannabis is subject to the recommendation of a specialist doctor and in accordance with a suitable license from the Ministry of Health according to law.


Pre-clinical studies have shown:

Canonic’s G150

Has Positive Results In It’s Anti-Inflammatory And Pain Relief Properties.

In pre-clinical studies reported on January 2022, Canonic screened multiple cannabis varieties from its diverse genetic collection for anti-inflammatory and pain relief properties. The varieties had been selected based on their active compounds compositions using Evogene’s GeneRator AI tech engine. The screening of the selected varieties was conducted in two separate models – in an in-vitro model at the laboratory of Prof. Reuven Or at the Hadassah Medical Center and in an in-vivo (fish larvae) model at Migal – Galilee Research Institute. Several varieties, including the cannabis variety which is the basis for Canonic’s product G150, exhibited consistent positive results in both model systems, over several repetitions and independent cultivation cycles.

Based on these results, Canonic has filed a patent application for several of these cannabis varieties and their medical effects.


“We would all like to think that cannabis represents a potential solution for specific, difficult to treat, medical conditions, such as pain or inflammatory diseases, for which we lack ideal treatments. After all, it would be poetic if nature’s wisdom provided the medicine we have not yet designed ourselves. The ability of Canonic’s medical cannabis varieties in reducing pain and inflammation in pre-clinical settings is impressive. Indeed, breeding whole cannabis plants such that they contain specific compounds in specific quantities and tailored ratios in order to hit the right disease targets with minimal adverse events is what we should aim for in order to benefit our society. And this is exactly what Canonic does.”

Prof. Yosi Tom

Managing Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem & Advisor to Canonic



* The studies were conducted under laboratory and live model conditions in fish, and did not include a clinical trial in humans.

** The above is provided as an informational overview, Canonic does not provide any guaranties regarding the described effects, which may vary among patients.

***The foregoing should not be construed as advertising and/or a recommendation and/or encouragement to use cannabis for non-medical purposes, which is prohibited by law. The use of medical cannabis is at the recommendation of a specialist and according to an appropriate license from the Ministry of Health in accordance with the law.


Together With You

You can help us develop better products! Canonic invites you to share with us experiences from the treatment. Combined with our extensive genetic databases, your feedback can help create strains that are better suited to patients’ needs. Join us, and together we will improve the therapeutic experience.

More Products

Mash Kush

T20/C4 Indica


T20/C4 Indica



T20/C4 Sativa

G150 OIL

T20/C4 Sativa

G200 OIL

T20/C4 Indica


T20/C4 Indica